BioWorld. Link to homepage.
BioWorld
BioWorld Science
BioWorld Asia
Data Snapshots
Biopharma
Medical technology
Infographics: Dynamic digital data analysis
Index insights
NME Digest
Special reports
Infographics: Dynamic digital data analysis
Trump administration impacts
Under threat: mRNA vaccine research
BioWorld at 35
Biopharma M&A scorecard
Bioworld 2025 review
BioWorld MedTech 2025 review
BioWorld Science 2025 review
Women's health
China's GLP-1 landscape
PFA re-energizes afib market
China CAR T
Alzheimer's disease
Coronavirus
More reports can be found here
BioWorld. Link to homepage.
Sign In
Sign Out
My Account
Subscribe
BioWorld - Friday, February 13, 2026
Home
»
Newsletters
» BioWorld Science
BioWorld Science
Oct. 2, 2020
View Archived Issues
CSL begins phase II study of CSL-346 in diabetic kidney disease
Read More
Optimization of selective TLR7/TLR8 dual antagonists using a new antagonist competition assay
Read More
Discovery of new potent, selective and orally bioavailable inhibitors of factor XI
Read More
Roche opens enrollment in phase III studies of crovalimab for PNH
Read More
New phase I/II study evaluates melanoma peptide vaccine with adjuvants
Read More
FDA approves Simponi Aria for pJIA and PsA in pediatric patients
Read More
Sorrento and ViralClear to explore combination therapy against COVID-19
Read More
FDA accepts IND application for phase IIb/III study of mesdopetam in PD-LIDs
Read More
Yangtze River Pharmaceutical, Shanghai Haiyan Pharmaceutical Technology patent BTK inhibitors
Read More
Macrophage migration inhibitory factor inhibitors discovered at Immunophage Biomedical
Read More
Alterity Therapeutics identifies compounds that modulate biological metals
Read More
Zhejiang Huahai Pharmaceutical, Shanghai Synergy Pharmaceutical Sciences disclose JAK inhibitors
Read More
AbbVie, Calico Life Sciences discover PTPN1/2 inhibitors
Read More
Enrollment begins in phase I/II study of 4D-310 gene therapy
Read More
Stem cells can help stem Klebsiella infection
Read More
Phase I study results with ST-617 for oral mucositis lead to phase II planning
Read More
Results from JAVELIN Head & Neck 100: avelumab fails in combination with chemoradiation
Read More
Overall survival data presented from phase III from SOLAR-1 study of alpelisib plus fulvestrant
Read More
Baylx gets IND approval to conduct study of BX-U001 in patients with COVID-19
Read More
Survival not improved with vandetanib added to fulvestrant in metastatic ER+ breast cancer
Read More
FDA clears IND for phase I studies of TNB-486 in B-cell malignancies
Read More
IntraBio's multinational trial of IB-1001 in Niemann-Pick disease type C meets primary endpoint
Read More
FDA lifts clinical hold on Solid's phase I/II study of SGT-001 in DMD
Read More
FDA issues complete response letter for remestemcel-L in pediatric steroid-refractory acute GvHD
Read More
